Bio-Rad Laboratories Inc stock has seen a
plunge of 4.42% on May 21 and an overall downward trend in the past few years. Despite this, the company's overall outlook remains hopeful with some analysts putting forward a case for the stock being
undervalued given the company's
low debt. Several updates including the First Pacific Advisors, LP adding 214,705 shares spark notable interest. Following Q1 2025 earning report, the stock showed movements in aftermarket trading. Although significant losses were noted, it's found to be a preferred pick amongst
institutional investors. Major news includes the offering to acquire
Stilla, continuing to signal towards future growth and expansion for the business. While revenue challenges and a price target revision by Citigroup have hit the stock,
increasing profit margins and its ongoing stake in Sartorius present prospective long-term value. Furthermore, its expanding international revenue shows promising signs of stability. Despite being labelled overvalued by some, others believe Bio-Rad offers a solid financial profile with new executive changes and a four-part plan for success. A bearish outlook was shared by several big-name firms such as Wells Fargo, Citigroup and UBS Group cutting their price targets.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jun 2018 02:34:36 GMT to Sat, 24 May 2025 07:26:57 GMT -
Rating -4
- Innovation 6
- Information 8
- Rumor -3
